{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:20:10Z","timestamp":1787775610742,"version":"build-2784847793"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Treatment of the patients with multidrug-resistant tuberculosis (MDR-TB)\/HIV coinfection in a state of severely suppressed immune system remains unsatisfactory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      The study involved 52 HIV-positive patients with MDR-TB and CD4+ lymphocyte cells below 50 cells\/\u03bcCL. Patients in control group (Group 1) and in basic group (Group 2) received standard treatment with second-line antituberculosis agents and antiretroviral agents. In addition, the patients in basic group were treated by immunoglobulin G (IgG) intravenously. Immunological diagnostics with the determination of the level of lymphocytes subgroups (CD3+, CD4+, CD8+, CD4+\/CD8+) was carried out using an AQUIOS\u2122 CL flow cytometry device at the beginning and after 3\u201320 months of treatment. Statistical analysis was performed using the Statistica 10.0 software (Stat. Soft Inc., USA). Results: In the patients of Group 2, the absolute number of CD3+ and CD4+ cells at the end of the 20th month of the treatment normalized in 26.9% (absolute amount) and 42.3% (relative amount) of subjects, while in Group 1, this indicator remained below the normal level (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). The addition of IgG into standard therapy caused normalization of CD8+ count in 76.9% of patients, while in the control group-only in 46.2% of patients (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Conclusions: The administration of IgG in combination with standard anti-tuberculosis and antiretroviral therapy (ART) contributes to the normalization of the cellular immunity status in patients with MDR-TB\/HIV coinfection and severe immunosuppression and allows you to start ART earlier than in patients with single standard therapy\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_21_21","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T16:21:32Z","timestamp":1725294092000},"page":"122-128","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The Impact of IgG Administration on the Cellular Immunity Status in the Patients with Multidrug-Resistant tuberculosis\/HIV with CD4 + Lymphocyte Cells below 50 Cells\/ \u03bcl"],"prefix":"10.4103","volume":"10","author":[{"given":"Nina","family":"Matsegora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonina","family":"Kaprosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petro","family":"Antonenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20240902","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/COH.0000000000000495","article-title":"Challenges of TB and HIV co-treatment: Updates and insights","volume":"13","author":"Tornheim","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"R2-4-20240902","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1164\/ajrccm.153.4.8616569","article-title":"Tuberculosis in HIV-positive patients: Cellular response and immune activation in the lung","volume":"153","author":"Law","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"R4-4-20240902","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/S1472-9792(13)70012-X","article-title":"Mycobacterium tuberculosis-specific CD8+ T cell recall in convalescing TB subjects with HIV co-infection","volume":"93","author":"Ongaya","year":"2013","journal-title":"Tuberculosis (Edinb"},{"key":"R5-4-20240902","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/cid\/cix1125","article-title":"Improved survival and cure rates with concurrent treatment for multidrug-resistant tuberculosis \u2013 Human immunodeficiency virus coinfection in South Africa","volume":"66","author":"Brust","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R6-4-20240902","first-page":"268","article-title":"Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis","volume":"7","author":"Geldmacher","year":"2012","journal-title":"Curr Opin HIV AIDS"},{"key":"R7-4-20240902","first-page":"16","article-title":"The indications and safety of polyvalent immunoglobulin for postexposure prophylaxis of hepatitis A, rubella and measles","volume":"19","author":"Young","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"R8-4-20240902","first-page":"559","article-title":"Intravenous immunoglobulin in septic shock: Review of the mechanisms of action and meta-analysis of the clinical effectiveness","volume":"82","author":"Busani","year":"2016","journal-title":"Minerva Anestesiol"},{"key":"R9-4-20240902","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/s100720200011","article-title":"High-dose intravenous immunoglobulin G treatment of myasthenia gravis","volume":"23","author":"Ferrero","year":"2002","journal-title":"Neurol Sci"},{"key":"R10-4-20240902","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1440-0960.2009.00578.x","article-title":"The use of intravenous immunoglobulin for treatment of dermatological conditions in Australia: A review","volume":"51","author":"Smith Saxon","year":"2010","journal-title":"Australas J Dermatol"},{"key":"R11-4-20240902","first-page":"41","article-title":"The effectiveness of immunoglobulin-G in patients with DRTB\/HIV in a state of expressive immunosuppression according to hematological studies. Tuberculosis, lung diseases, HIV-infection","volume":"2","author":"Matsegora","year":"2018","journal-title":"Tuberculosis, lung diseases, HIV-infection"},{"key":"R12-4-20240902","doi-asserted-by":"crossref","first-page":"46","DOI":"10.30978\/TB2019-1-46","article-title":"Clinical case of immunoglobulin G application with \u0441hemo-resistant tuberculosis in combination with HIV-infection with severe immunosuppression. Tuberculosis, lung diseases, HIV-infection","volume":"1","author":"Matsegora N\u0410 Kaprosh","year":"2019","journal-title":"Tuberculosis, lung diseases, HIV-infection"},{"key":"R13-4-20240902","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4103\/ijmy.ijmy_122_19","article-title":"Biochemical value dynamics in patients with multidrugresistant tuberculosis\/HIV with CD4+ lymphocyte cells below 50 cells\/\u03bccL and its variability in the application of adjuvant immunoglobulin therapy","volume":"8","author":"Matsegora Nina","year":"2019","journal-title":"Int J Mycobacteriol"},{"key":"R14-4-20240902","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1177\/2325957415599210","article-title":"The effect of early initiation of antiretroviral therapy in TB\/HIV-coinfected patients: A systematic review and meta-analysis","volume":"14","author":"Abay Solomon","year":"2015","journal-title":"J Int Assoc Provid AIDS Care"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_21_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:35:29Z","timestamp":1787772929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_21_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_21_21","relation":{},"ISSN":["2212-5531"],"issn-type":[{"value":"2212-5531","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}